Ann M Rasmusson1,2,3, Suzanne L Pineles4,5,6. 1. National Center for PTSD, Women's Health Science Division, Department of Veterans Affairs, 150 South Huntington Avenue, Boston, MA, 02130, USA. ann.rasmusson@va.gov. 2. VA Boston Healthcare System, 150 South Huntington Avenue, Boston, MA, 02130, USA. ann.rasmusson@va.gov. 3. Boston University School of Medicine, 72 E Concord St, Boston, MA, 02118, USA. ann.rasmusson@va.gov. 4. National Center for PTSD, Women's Health Science Division, Department of Veterans Affairs, 150 South Huntington Avenue, Boston, MA, 02130, USA. 5. VA Boston Healthcare System, 150 South Huntington Avenue, Boston, MA, 02130, USA. 6. Boston University School of Medicine, 72 E Concord St, Boston, MA, 02118, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes neurotransmitter, peptide, and other neurohormone abnormalities associated with posttraumatic stress disorder (PTSD) and relevant to development of precision medicine therapeutics for PTSD. RECENT FINDINGS: As the number of molecular abnormalities associated with PTSD across a variety of subpopulations continues to grow, it becomes clear that no single abnormality characterizes all individuals with PTSD. Instead, individually variable points of molecular dysfunction occur within several different stress-responsive systems that interact to produce the clinical PTSD phenotype. Future work should focus on critical interactions among the systems that influence PTSD risk, severity, chronicity, comorbidity, and response to treatment. Effort also should be directed toward development of clinical procedures by which points of molecular dysfunction within these systems can be identified in individual patients. Some molecular abnormalities are more common than others and may serve as subpopulation biological endophenotypes for targeting of currently available and novel treatments.
PURPOSE OF REVIEW: This review summarizes neurotransmitter, peptide, and other neurohormone abnormalities associated with posttraumatic stress disorder (PTSD) and relevant to development of precision medicine therapeutics for PTSD. RECENT FINDINGS: As the number of molecular abnormalities associated with PTSD across a variety of subpopulations continues to grow, it becomes clear that no single abnormality characterizes all individuals with PTSD. Instead, individually variable points of molecular dysfunction occur within several different stress-responsive systems that interact to produce the clinical PTSD phenotype. Future work should focus on critical interactions among the systems that influence PTSD risk, severity, chronicity, comorbidity, and response to treatment. Effort also should be directed toward development of clinical procedures by which points of molecular dysfunction within these systems can be identified in individual patients. Some molecular abnormalities are more common than others and may serve as subpopulation biological endophenotypes for targeting of currently available and novel treatments.
Authors: M Maes; H Westenberg; E Vandoolaeghe; P Demedts; A Wauters; H Neels; H Y Meltzer Journal: J Clin Psychopharmacol Date: 1997-10 Impact factor: 3.153
Authors: Mathias Zink; Christiane Otto; Björn Zörner; Christiane Zacher; Günther Schütz; Fritz A Henn; Peter Gass Journal: Neurosci Lett Date: 2004-04-22 Impact factor: 3.046
Authors: Renu Sah; Nosakhare N Ekhator; Jeffrey R Strawn; Floyd R Sallee; Dewleen G Baker; Paul S Horn; Thomas D Geracioti Journal: Biol Psychiatry Date: 2009-07-03 Impact factor: 13.382
Authors: Judith K Bass; Jeannie Annan; Sarah McIvor Murray; Debra Kaysen; Shelly Griffiths; Talita Cetinoglu; Karin Wachter; Laura K Murray; Paul A Bolton Journal: N Engl J Med Date: 2013-06-06 Impact factor: 91.245
Authors: Ann M Rasmusson; Matthew W King; Ivan Valovski; Kristin Gregor; Erica Scioli-Salter; Suzanne L Pineles; Mohamed Hamouda; Yael I Nillni; George M Anderson; Graziano Pinna Journal: Psychoneuroendocrinology Date: 2018-11-22 Impact factor: 4.905
Authors: Kristen Nishimi; Rebecca C Thurston; Lori B Chibnik; Andrea L Roberts; Jennifer A Sumner; Rebecca B Lawn; Shelley S Tworoger; Yongjoo Kim; Karestan C Koenen; Laura D Kubzansky Journal: J Psychosom Res Date: 2022-05-21 Impact factor: 4.620
Authors: Jennifer R Fonda; Kristin L Gregor; Catherine B Fortier; Erica R Scioli-Salter; Regina E McGlinchey; Ann Rasmusson Journal: Psychopharmacology (Berl) Date: 2019-01-07 Impact factor: 4.530
Authors: Ana Teresa D D'Elia; Mario F Juruena; Bruno M Coimbra; Marcelo F Mello; Andrea F Mello Journal: BMC Psychiatry Date: 2021-03-31 Impact factor: 3.630
Authors: Byung Kil Kim; Jennifer R Fonda; Richard L Hauger; Graziano Pinna; George M Anderson; Ivan T Valovski; Ann M Rasmusson Journal: Neurobiol Stress Date: 2020-04-18